Company (Location)

Funding Institution

Amount (M)

Type

Details (Date)

Aastrom Biosciences Inc. (Ann Arbor, Mich.)

National Institutes of Health

$0.1

Phase I Small Business Innovation Research grant (SBIR)

Aastrom will use the funding to support the development of ex vivo generation of cells for use in accelerating platelet regeneration following autologous bone marrow transplantation (7/99)

Aquila Biopharmaceuticals Inc. (Framingham, Mass.)

National Institute of Allergy and Infectious Diseases

$0.9

Phase II SBIR

The grant will provide two-year funding to support the development of novel vaccines for tuberculosis based on CDI immune enhancement technology (8/99)

Aurora Biosciences Corp. (San Diego)

National Cancer Institute

$0.1

Phase I SBIR

Aurora will use the grant to develop methods for the identification of immunomodulatory agents using its GenomeScreen technology (1/99)

National Cancer Institute

$0.1

SBIR

The grant will give Aurora funding to use its GenomeScreen technology to identify gene targets and compounds for breast cancer (3/99)

BioPhysics Assay Laboratory Inc. (Wellesley, Mass.)

National Heart, Lung, and Blood Institute

ND

Phase I SBIR

BioPhysics will use the funding for the in vivo measurement of regional blood flow by a novel neutron activation-based technology (3/99)

Cell Therapeutics Inc. (Seattle) and The University of Virginia (Charlottesville, Va.)

Juvenile Diabetes Foundation International

$1.6

Research grant

Cell Therapeutics and the Univ. of Va. will use the funding to investigate novel approaches to early intervention and prevention of Type I diabetes (8/99)

CoCensys Inc. (Irvine, Calif.)

National Institutes of Health

ND

Phase I SBIR

CoCensys will use the grant to continue discovery of novel nociceptin/orphanin FQ receptor antagonists to treat acute and chronic pain (4/99)

National Institute of Neurological Disorders and Stroke

ND

Phase II SBIR

The company will use the grant to discover compounds that are caspase inhibitors (6/99)

Cognetix Inc. (Salt Lake City)

National Institutes of Health

$0.8

Phase II SBIR

Cognetix will use the funding to advance high-throughput assay and functional characterization technologies; funding will also support development of quantitative fluorescent imaging techniques and test kits for detecting physiological activities of agents in live cell assays (4/99)

Copernicus Therapeutics Inc. (Cleveland)

Cystic Fibrosis Foundation

$1.5

Phase II

Phase II grant will support preclinical and early clinical development of PLASmin Complexes that enable delivery of therapeutic genes via the blood-stream to cells lining the airways and lungs of patients with cystic fibrosis (1/99)

National Cancer Institute

$0.25

Research grant

Copernicus will use the funding to support development of its REPLIsome delivery technologies, which enable control over the dose and duration of gene therapy products (3/99)

Cortex Pharmaceuticals Inc. (Irvine, Calif.)

National Institutes of Health

$0.1

SBIR

Cortex will use the funding to support ongoing research into AMPA-modulating compounds for treating patients who have had a recent stroke, head injury or brain surgery (5/99)

Cypros Pharmaceutical Corp. (Carlsbad, Calif.)

National Institutes of Health

$0.75

Phase II SBIR

Cypros will use the grant to fund further development of its compounds to protect the brain from ischemic injury (4/99)

CytRyx Corp. (Atlanta)

FDA's division of Orphan Drug Product Development

$0.4

Research grant

CytRx received the second and final installment of a $0.4M grant to support ongoing study of Flocor for the treatment of sickle-cell vasco-occlusive crisis (5/99)

Demegen Inc. (Pittsburgh)

National Heart, Lung, and Blood Institute

$0.1

SBIR

Demegen will use the grant to study the effectiveness of its compounds in treating multi-drug-resistant bacterial infections in animal models (1/99)

Diatide Inc. (Londonderry, N.H.) and Brookhaven National Laboratory (Brookhaven, N.Y.)

Department of Energy

$0.75

Research grant

Diatide and Brookhaven will use the three-year grant to develop Stanamet (tin-117m DTPA) technology for treating bone cancer (6/99)

Discovery Laboratories Inc. (Doylestown, Pa.)

Cystic Fibrosis Foundation

$0.8

Matching funds Therapeutics Development Grant

The grant will fund a recently initiated Phase IIa trial of SuperVent aerosol solution in cystic fibrosis patients (8/99)

EPIcyte Pharmaceutical Inc.

National Institutes of Health

ND

Phase I SBIR

EPIcyte received two SBIR grants to further the development of antibodies for reproductive health applications (3/99)

Epimmune Inc. (San Diego)

National Institutes of Health

$2.25

5-year research contract

Epimmune will use the funding to further enhance its proprietary Epitope Identification System, which enables the identification and validation of T-cell epitopes from gene sequences (5/99)

Gamma-A Technologies Inc. (Herndon, Va.)

National Institutes of Health

$0.1

SBIR

Gamma-A will use the funding to support a feasibility study on the use of locally delivered human immunoglobulin, IgG, polyclonal antibodies, to reduce the incidence of hospital-acquired bacterial pneumonia associated with endotracheal tubes (8/99)

Genelabs Technologies Inc. (Redwood City, Calif.)

Defense Advanced Research Projects Agency

$4.8

Research grant

The company's three-year grant will be funded for a second year for continuing research into biological defense (2/99)

GeneMedicine Inc. (Merged with MegaBios Corp. 3/99 to form Valentis Inc.; The Woodlands, Texas)

National Institutes of Health

$0.8

SBIR

GeneMedicine received two grants totaling $0.8M to fund the development of improved tissue-specific gene therapy expression systems; one grant will go toward finding an optimal promoter to be used with a human VEGF expression plasmid, for ischemia (3/99)

GeneTrace Systems Inc. (Alameda, Calif.)

National Institute of Environmental Health Sciences

ND

SBIR

GeneTrace will use the grant to fund the development of its high-throughput capability for SNP analysis using mass spectrometry (7/99)

National Cancer Institute

ND

SBIR

GeneTrace will use the grant to fund high-throughput expression monitoring of multiplexed cancer gene sets and their responses to changes in their environment (7/99)

Genetronics Biomedical Ltd. (San Diego)

National Institutes of Health

$0.1

Phase I SBIR

Genetronics will use the funding for the study of in vivo skin-targeted gene therapy by electroporation (4/99)

Genomica Corp. (Boulder, Colo.)

National Cancer Institute

$0.1

Research and development grant

Genomica will use the grant to develop a system for analyzing gene expression for cancer gene discovery, targeted toward the company's software suite product, Expression Manager (3/99)

GenoPlex Inc. (Denver)

National Institutes of Health

$0.1

SBIR

GenoPlex will use the funding to characterize the tkr-1 gene and to support research into developing screens (5/99)

Genzyme Corp. (Cambridge, Mass.)

Cystic Fibrosis Foundation

$1.05

Research grant

Genzyme will use the funding for research to identify small-molecule drugs to treat cystic fibrosis; the company will develop high-throughput screens to identify compounds that improve chloride ion transport, or repair the protein defect that causes cystic fibrosis in some patients (6/99)

IGT Pharma (Vancouver, British Columbia)

Science Council of British Columbia

ND

Technology BC industry grant

IGT will use the funding to develop a novel class of podophyllotoxin analogues as new anti-cancer agents for the treatment of various cancers, including those that are multidrug resistant (4/99)

Inhibitex Inc. (Alpharetta, Ga.)

National Institute of Allergy and Infectious Diseases

$0.1

Phase I SBIR

Inhibitex will use the funding to test the efficacy of its MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) -based vaccine against antibiotic-resistant Staphylococcus aureus in preclinical models (8/99)

Kinetek Pharmaceuticals Inc. (Vancouver, British Columbia)

Industrial Research Assistance Program (of National Research Council Canada)

$0.35

Research grant

Kinetek will use the grant to continue funding its functional proteomics program, Kineomics, which integrates functional proteomics and bioinformatics to identify those protein kinases that show aberrant enzymatic activity in the disease state (2/99)

Kosan Biosciences Inc. (Haywood, Calif.)

National Institutes of Health

ND

Phase I Small Business Technology Transfer Research grant (STTR)

Kosan will use the grant to research novel analogues of rapamycin and FK506 for nerve regeneration (4/99)

Large Scale (Rockville, Md.)

National Institutes of Health

ND

Phase II SBIR

Large Scale will use the funding to further develop a high-throughput, high-sensitivity detection technology for protein on 2-D gels (6/99)

Lerner Research Institute (a unit of the Cleveland Clinic; Cleveland)

Department of Defense

$3

Research and development award

Lerner will use the two-year funding to to begin development of new methods of regenerating tissue and bone in trauma patients (8/99)

Lerner Research Institute and Cole Eye Institute (units of the Cleveland Clinic; Cleveland)

The Foundation Fighting Blindness Inc.

$1.5

Research and development award

The award will be used to fund a series of five projects related to the causes and prevention of inherited retinal disease, including age-related macular degeneration (8/99)

Magainin Pharmaceuticals Inc. (Plymouth Meeting, Pa.)

National Cancer Institute

$0.1

SBIR

Magainin will use the grant to support development of an abbreviated synthetic route for squalamine, an antiangiogenic agent (3/99)

Neurobiological Technologies Inc. (Richmond, Calif.)

National Institutes of Health

$0.1

SBIR

Neurobiological will use the grant to continue development of its anti-edema agent, Xerecept, for treating peritumoral brain edema, and to continue patient enrollment and treatment in a Phase II trial (2/99)

Palatin Technologies Inc. (Princeton, N.J.)

Department of Health and Human Services

$0.1

Phase I SBIR

Palatin will use the grant for the develment of an obesity treatment based on the company's proprietary MIDAS drug discovery technology (2/99)

Department of Health and Human Services

$0.75

Phase II SBIR

Palatin will use the Phase II grant for completing work on an imaging agent (2/99)

PathoGenesis Corp. (Seattle)

Cystic Fibrosis Foundation

$1.5

Research grant

PathoGenesis will use the two-year funding to identify novel classes of antibiotics and potential drug candidates to treat serious lung infections, particularly those caused by Pseudomonas aeruginosa (8/99)

Periodontix Inc. (Watertown, Mass.)

Cystic Fibrosis Foundation

$0.2

Research and development grant

Periodontix will use the grant to continue development of its histanin peptide, P-113, to treat chronic lung infec tions associated with cystic fibrosis (2/99)TD>

Pharmazyme (a division of Immune Complex Corp.; San Diego)

National Institute of Environmental Health Sciences

$0.1

Phase I SBIR

Pharmazyme will use the award to fund the development of its high through put assay system for the detection of human cytochrome P450 polymorphisms (8/99)

Phytera Inc. (Hayward, Calif.)

National Institute of Allergy and Infectious Disease

ND

Phase I SBIR

Phytera will use the grant to develop new tools for antibacterial drug discovery (4/99)

Progenics Pharmaceuticals Inc. (Tarrytown, Pa.)

National Institute of Allergy and Infectious Diseases

$2

Phase II SBIR

Progenics will use the grant to support the development of monoclonal antibodies that target the cellular co-receptors required for HIV to fuse with target cells (7/99)

National Institute of Allergy and Infectious Diseases

$1

SBIR

Progenics will use the grant to fund continuing development of novel HIV vaccines (7/99)

ProScript Inc. (Cambridge, Mass.)

National Institutes of Health

ND

Phase I SBIR

ProScript will use the grant to support the development of PS-519 for the treatment of stroke and reperfusion injury (4/99)

ProteoTech Inc.

National Institutes of Health

$0.4

Research grants

Proteotech received two grants to study the cause, prevention and treatment of brain amyloid deposits associated with Alzheimer's disease (4/99)

Repligen Corp. (Needham, Mass.)

National Cancer Institute

ND

Phase I SBIR

Repligen will use the grant to support the characterization of inhibitors of heparanase in a combinatorial library of organic compounds (8/99)

Repligen Corp. (Needham, Mass.)

National Science Foundation

ND

Phase I SBIR

Repligen will use the grant to fund the synthesis of a combinatorial library of organic compounds that will be screened for their ability to selectively extract biopharmaceutical proteins from complex production media (8/99)

SciClone Pharmaceuticals Inc. (San Mateo, Calif.)

Cystic Fibrosis Foundation

$0.5

Phase II grant

SciClone will use the funding for an ongoing Phase II study of CPX, a drug designed to target an underlying protein-associated defect that causes cystic fibrosis in some patients (4/99)

Structural Bioinformatics Inc. (San Diego)

National Institutes of Health

$0.1

SBIR

Structural Bioinformatics will use the grant to develop non-peptide, small molecule antagonists targeting the HER-2 gene (4/99)

National Institutes of Health

$0.1

SBIR

The company will use the grant to develop non-peptide, small-molecule inhibitors targeting a bacterial metalloproteinase (5/99)

National Institute of Allergy and Infectious Diseases

$0.1

Phase I SBIR

The company will use the grant for the development of non-peptide small molecules for asthma treatment (8/99)

The Whitehead Institute for Biomedical Research (Cambridge Mass.), Washington University School of Medicine (St. Louis) and Baylor College of Medicine (Houston)

National Human Genome Research Institute (NHGRI)

$81.6

Research grant

NHGRI awarded $35M to the Whitehead Institute, $33.2M to Washington University School of Medicine, and $13.4M to Baylor College of Medicine; the funds will be used by the laboratories, as part of an international consortium, to accelerate the sequencing of the human genome and to create a working draft by spring 2000 (3/99)

TOTAL: $111.2M

Notes:

* This chart covers grants and awards to biotechnology companies, university laboratories collaborating with biotechnology companies, and research divisions of hospitals and clinics.

ND = Not Disclosed